DekaBank Deutsche Girozentrale cut its position in shares of AbbVie Inc (NYSE:ABBV) by 0.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 405,599 shares of the company’s stock after selling 2,174 shares during the period. DekaBank Deutsche Girozentrale’s holdings in AbbVie were worth $29,019,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ABBV. Acropolis Investment Management LLC bought a new position in shares of AbbVie in the 2nd quarter valued at approximately $106,000. Hudock Capital Group LLC raised its stake in shares of AbbVie by 109.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after acquiring an additional 806 shares in the last quarter. Ffcm LLC raised its stake in shares of AbbVie by 167.2% in the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after acquiring an additional 963 shares in the last quarter. Bristlecone Advisors LLC bought a new position in shares of AbbVie in the 3rd quarter valued at approximately $113,000. Finally, BDO Wealth Advisors LLC bought a new position in shares of AbbVie in the 2nd quarter valued at approximately $115,000. 69.22% of the stock is owned by institutional investors.

In other news, insider Henry O. Gosebruch sold 18,300 shares of AbbVie stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the sale, the insider now owns 81,287 shares of the company’s stock, valued at approximately $7,360,537.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Severino sold 25,633 shares of AbbVie stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $94.69, for a total value of $2,427,188.77. Following the sale, the executive vice president now directly owns 114,922 shares in the company, valued at approximately $10,881,964.18. The disclosure for this sale can be found here. Insiders have sold a total of 494,676 shares of company stock worth $47,237,938 in the last three months. 0.23% of the stock is owned by insiders.

A number of brokerages recently weighed in on ABBV. Zacks Investment Research downgraded AbbVie from a “buy” rating to a “hold” rating in a research note on Monday. Leerink Swann set a $106.00 price target on AbbVie and gave the stock a “buy” rating in a research report on Tuesday, December 5th. Argus lifted their price target on AbbVie from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, September 29th. UBS Group downgraded AbbVie from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $79.00 to $92.00 in a research report on Monday, September 25th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $107.00 price target on shares of AbbVie in a research report on Thursday, September 28th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $101.38.

AbbVie Inc (NYSE ABBV) opened at $106.49 on Tuesday. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. The company has a market capitalization of $167,050.42, a P/E ratio of 25.91, a price-to-earnings-growth ratio of 1.22 and a beta of 1.52. AbbVie Inc has a 1 year low of $59.27 and a 1 year high of $106.54.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. During the same quarter last year, the firm earned $1.21 EPS. AbbVie’s revenue for the quarter was up 8.8% compared to the same quarter last year. equities analysts anticipate that AbbVie Inc will post 5.56 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.67%. The ex-dividend date is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio (DPR) is presently 69.10%.

WARNING: This article was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://theolympiareport.com/2018/01/23/dekabank-deutsche-girozentrale-sells-2174-shares-of-abbvie-inc-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.